FibroGen Inc (FGEN)
1.18
+0.02
(+1.72%)
USD |
NASDAQ |
May 02, 11:02
FibroGen Gross Profit Margin (Quarterly): 80.08% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 80.08% |
| September 30, 2023 | 89.43% |
| June 30, 2023 | 87.12% |
| March 31, 2023 | 90.35% |
| December 31, 2022 | 85.67% |
| September 30, 2022 | 72.62% |
| June 30, 2022 | 77.16% |
| March 31, 2022 | 93.03% |
| December 31, 2021 | 81.11% |
| Date | Value |
|---|---|
| September 30, 2021 | 97.91% |
| June 30, 2021 | 87.37% |
| March 31, 2021 | 91.15% |
| December 31, 2020 | 95.98% |
| September 30, 2020 | 94.99% |
| June 30, 2020 | 92.83% |
| March 31, 2020 | 96.02% |
| December 31, 2019 | 88.65% |
| September 30, 2019 | 99.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
72.62%
Minimum
Sep 2022
99.27%
Maximum
Sep 2019
88.93%
Average
89.89%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Annovis Bio Inc | -- |
| Emergent BioSolutions Inc | 31.42% |
| Geron Corp | -- |
| Vertex Pharmaceuticals Inc | 85.38% |
| Regulus Therapeutics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -55.78% |
| Profit Margin (Quarterly) | -207.2% |
| Operating Margin (Quarterly) | -199.7% |
| Return on Net Operating Assets | -115.0% |